CRSP CRISPR Therapeutics
- 60.570
- -1.215-1.97%
- 60.450
- -0.120-0.20%
CRISPR Therapeutics News
CRISPR Therapeutics Stock (NASDAQ:CRSP): Will It Take Off Anytime Soon?
Top Gap Ups and Downs on Monday: AVGO, DELL, SONY and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Crispr Therapeutics Price Target Maintained With a $105.00/Share by Piper Sandler
Crispr Therapeutics Price Target Maintained With a $105.00/Share by Piper Sandler
Express News | Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Maintains $105 Price Target
Needham Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $88
Needham analyst Gil Blum maintains $CRISPR Therapeutics(CRSP.US)$ with a buy rating, and maintains the target price at $88.According to TipRanks data, the analyst has a success rate of 0.0% and a tota
Piper Sandler Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $105
Piper Sandler analyst Edward Tenthoff maintains $CRISPR Therapeutics(CRSP.US)$ with a buy rating, and maintains the target price at $105.According to TipRanks data, the analyst has a success rate of 0
Express News | Needham Reiterates Buy on CRISPR Therapeutics, Maintains $88 Price Target
CRISPR Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/17/2024 38.36% Needham $88 → $88 Reiterates Buy → Buy 05/23/2024 32.08% Citigroup $89 → $84 Maintains B
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
S&P 500 Futures Up In Premarket Trading; Broadcom, Tesla Lead
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Broadcom Inc. (AVGO) was up 13.8% in pre-market tra
CRISPR Therapeutics (CRSP) Presents at Goldman Sachs 45th Annual Global Healthcare Conference - Company Call Transcript
CRISPR Therapeutics (CRSP) Presents at Goldman Sachs 45th Annual Global Healthcare Conference - Company Call Transcript
CRISPR Therapeutics AG (CRSP) Is Attracting Investor Attention: Here Is What You Should Know
Why Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report?
CRISPR Therapeutics AG (CRSP) Jefferies 2024 Global Healthcare Conference (Transcript)
CRISPR Therapeutics AG (CRSP) Jefferies 2024 Global Healthcare Conference (Transcript)
William Blair Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
William Blair analyst Tim Lugo maintains $CRISPR Therapeutics(CRSP.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.8% and a total average return of 6.7% over th
BioLineRx Stock Jumps 14% on St. Jude Clinical Trial for Mitoxafortide
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
ZUG, Switzerland and BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise
The wave of US biopharmaceutical mergers and acquisitions has set off who will be the next potential target?
The Zhitong Finance App learned that Wells Fargo released its annual list of potential mergers and acquisitions in the biopharmaceutical industry, adding diet drug developers Viking Therapeutics (VKTX.US), gene editing company CRISPR Therapeutics (CRSP.US), and Intellia Therapeutics (NTLA.US) to the list of potential acquisition targets in 2024. The investment bank has identified 31 such companies in the biopharmaceutical small to medium cap sector, and these companies are highly or moderately suitable for the following large pharmaceutical companies
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
It's Probably Less Likely That CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Will See A Huge Pay Rise This Year
Key Insights CRISPR Therapeutics will host its Annual General Meeting on 30th of May CEO Sam Kulkarni's total compensation includes salary of US$724.5k The total compensation is similar to the ave
Analysis
Price Target
No Data
